Bruker Corporation $BRKR Shares Sold by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. has decreased its stake in Bruker Corporation by 31.8% in the first quarter, now holding 45,662 shares valued at approximately $1.9 million.
• Bruker reported its latest earnings on August 4, missing estimates with $0.32 EPS against a forecast of $0.33 and revenue of $797.4 million, below expectations of $811.17 million.
• The company recently announced a quarterly dividend of $0.05 per share, with a yield of 0.6%, payable on October 3, 2023.

Capital Fund Management S.A. trimmed its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 31.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,662 shares of the medical research company's stock after selling 21,292 shares during the quarter. Capital Fund Management S.A.'s holdings in Bruker were worth $1,906,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Pinnacle Bancorp Inc. bought a new position in shares of Bruker in the 1st quarter worth $29,000. Allworth Financial LP grew its stake in Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after purchasing an additional 745 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Bruker during the first quarter valued at about $42,000. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after buying an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Insider Activity at Bruker

In other news, CEO Frank H. Laukien bought 2,608 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were acquired at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the transaction, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. The trade was a 0.01% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 27.30% of the stock is owned by insiders.

Bruker Stock Performance

Shares of BRKR stock traded down $0.13 during trading hours on Thursday, hitting $33.46. The company's stock had a trading volume of 1,619,598 shares, compared to its average volume of 3,333,565. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The company has a 50 day moving average of $38.12 and a 200 day moving average of $40.46. Bruker Corporation has a 12-month low of $30.00 and a 12-month high of $72.94. The stock has a market cap of $5.08 billion, a PE ratio of 64.35, a price-to-earnings-growth ratio of 2.78 and a beta of 1.16.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.Bruker's revenue for the quarter was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, sell-side analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.6%. The ex-dividend date is Tuesday, September 23rd. Bruker's payout ratio is presently 38.46%.

Analysts Set New Price Targets

BRKR has been the subject of several recent analyst reports. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a "buy" rating in a research note on Monday, August 4th. Stifel Nicolaus set a $40.00 price target on Bruker and gave the stock a "hold" rating in a research report on Tuesday, August 5th. Citigroup decreased their price objective on Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. The Goldman Sachs Group lowered their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Finally, Bank of America reduced their target price on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Bruker currently has a consensus rating of "Hold" and an average target price of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.